Executive Summary

MARA is currently finalizing a series of reimbursement risk assessments across twelve drug–indication pairs spanning oncology, rare diseases, immunology, nephrology, and cardiovascular conditions.

These assessments have been initiated following material evidence availability across clinical datasets, comparator landscapes, and evolving therapeutic positioning. Each asset is being evaluated under the standardized MARA 10-domain framework.

The forthcoming publications will provide structured reimbursement probability signals, calibrated to historical HTA outcomes and comparable across assets, time, and portfolios.

This activity reflects ongoing surveillance rather than discrete announcement. It reinforces the role of MARA as a continuous, standardized benchmark in market-access risk evaluation.

Trigger and Structural Context

The initiation of these assessments reflects a convergence of late-phase clinical readouts, regulatory progression, and increasing visibility on comparator positioning across multiple therapeutic areas.

Assets under review include:

• relacorilant (platinum-resistant ovarian cancer)
• tividenofusp alfa-eknm (Hunter syndrome)
• icotrokinra (plaque psoriasis)
• linerixibat (primary biliary cholangitis)
• felzartamab (antibody-mediated rejection in kidney transplant)
• anito-cel (relapsed/refractory multiple myeloma)
• camizestrant (HR-positive, HER2-negative breast cancer)
• povetacicept (IgA nephropathy)
• brepocitinib (dermatomyositis)
• lonvo-z (hereditary angioedema)
• baxdrostat (treatment-resistant hypertension)

Across these assets, a common structural pattern emerges: clinical datasets are maturing, but alignment with HTA expectations—particularly around comparator relevance and cost-utility anchoring—remains variable.

This reinforces a persistent industry dynamic: clinical success does not automatically translate into reimbursement strength.

Domain-Level Drivers

The forthcoming assessments are primarily influenced by variation across three core domains: Clinical Effectiveness, Cost-Effectiveness, and Comparator Appropriateness.

Clinical Effectiveness
Several assets demonstrate statistically significant outcomes within controlled trial settings. However, the degree of incremental benefit versus relevant comparators remains a central determinant. In competitive classes such as oncology and immunology, even modest differences in progression-free survival or response rates can materially influence HTA positioning.

Cost-Effectiveness
Cost-utility modeling remains a key source of uncertainty. In multiple cases, immature overall survival data or limited HRQoL evidence increases sensitivity within incremental cost-effectiveness ratios. This typically translates into narrower price corridors and increased negotiation dependency.

Comparator Appropriateness
Comparator selection continues to act as a structural constraint. Trials using placebo or non-standard comparators introduce challenges in HTA translation, requiring indirect treatment comparisons that increase uncertainty and reduce pricing leverage.

These domain interactions are not asset-specific anomalies; they reflect recurring structural tensions between clinical development pathways and HTA evidence requirements.

What the Rating Means

Each forthcoming MARA rating will express reimbursement probability under HTA scrutiny using standardized rating bands:

A++ to A
Strong probability of broad reimbursement under HTA scrutiny.

B++
Marginal, finely balanced, reimbursement still achievable but sensitive to pricing and positioning.

B+ to C
Lower probability of reimbursement; increasing risk of price pressure, restriction, delay, or rejection.

These ratings do not predict outcomes. They provide a structured probability signal based on evidence alignment with historical HTA decisions.

Structural Implications for Stakeholders

For market access teams, these assessments highlight the continued importance of early comparator alignment and cost-effectiveness planning. Late-stage adjustments rarely resolve structural evidence gaps.

For investors and M&A stakeholders, comparability across assets becomes critical. Without a standardized benchmark, assets with similar clinical profiles may carry materially different reimbursement risk profiles.

For portfolio strategy, the implication is consistent: internal forecasts frequently overestimate reimbursement probability when not anchored to external, HTA-calibrated frameworks.

This raises a recurring governance question:

“If this pricing or launch decision is later challenged, what independent benchmark was relied upon?”

The absence of a defensible benchmark introduces structural bias into decision-making, particularly in late-stage asset valuation.

Methodological Integrity

All assessments are conducted using the MARA 10-domain framework, applied consistently across all assets.

This ensures comparability across time and portfolios. Each evaluation is calibrated to historical HTA outcomes and based exclusively on publicly available evidence.

Assessments are human-validated and subject to structured committee review. MARA operates under a continuous surveillance model, with ratings updated as material evidence emerges.

—

These forthcoming publications represent continued expansion of a standardized reimbursement risk signal across diverse therapeutic areas.

MARA will continue to monitor material evidence events and adjust the reimbursement risk signal accordingly.